Datapoint: Xolair Scores FDA Nod for Food Allergies

February 28

Genentech and Novartis’ Xolair (omalizumab) on Feb. 16 became the first drug approved to prevent severe reactions from accidental exposure to multiple food allergies. Administered every two to four weeks, the injectable can be used in certain patients aged 1 and older to reduce the risk of severe reactions from IgE-mediated food allergies, such as allergies to peanuts, eggs and milk. Xolair was first approved in 2003 for the treatment of moderate to severe asthma. For this indication, it currently holds covered or better status for 83% of all insured lives under the pharmacy benefit, and 96% of lives under the medical benefit.

SOURCE: MMIT Analytics, as of  2/26/24